Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency by Almalki A et al.
 Newcastle University ePrints 
 
Almalki A, Alston CL, Parker A, Simonic I, Mehta SG, He LP, Reza M, Oliveira 
JMA, Lightowlers RN, McFarland R, Taylor RW, Chrzanowska-Lightowlers 
ZMA. Mutation of the human mitochondrial phenylalanine-tRNA synthetase 
causes infantile-onset epilepsy and cytochrome c oxidase deficiency. 
Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease 2014, 1842(1), 
56-64. 
Copyright: 
©2013 The Authors. Published by Elsevier B.V. This is an open access article funded by Wellcome Trust. 
DOI link to article: 
http://dx.doi.org/10.1016/j.bbadis.2013.10.008 
Date deposited:  03-09-2014  
 
 
 
 
This work is licensed under a Creative Commons Attribution 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Biochimica et Biophysica Acta 1842 (2014) 56–64
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isMutation of the human mitochondrial phenylalanine-tRNA synthetase
causes infantile-onset epilepsy and cytochrome c oxidase deficiency☆Abdulraheem Almalki a,1, Charlotte L. Alston a, Alasdair Parker b, Ingrid Simonic c, Sarju G. Mehta d,
Langping He a, Mojgan Reza e, Jorge M.A. Oliveira a,2, Robert N. Lightowlers f, Robert McFarland a,
Robert W. Taylor a,⁎, Zofia M.A. Chrzanowska-Lightowlers a,⁎⁎
a Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
b Child Development Centre, Addenbrooke's Hospital, Cambridge, UK
c Medical Genetics Laboratories, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
d Department of Medical Genetics, Addenbrookes Hospital, Cambridge, UK
e Biobank, Institute for Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK
f The Wellcome Trust Centre for Mitochondrial Research, Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UKAbbreviations: OXPHOS, oxidative phosphorylation;
tase; mt-, mitochondrial; mtDNA, mitochondrial DNA;MR
LBSL, leukoencephalopathy with brain stem and spinal co
vation; PCH6, pontocerebellar hypoplasia type 6; MLASA
sideroblastic anaemia
☆ This is an open-access article distributed under the t
Attribution License, which permits unrestricted use, dis
any medium, provided the original author and source are
⁎ Corresponding author. Tel.: +44 191 2223685; fax: +
⁎⁎ Corresponding author. Tel.: +44 191 2228028; fax: +
E-mail addresses: abdulraheem.almalki@newcastle.ac.
charlotte.alston@newcastle.ac.uk (C.L. Alston), alasdair.pa
(A. Parker), ingrid.simonic@addenbrookes.nhs.uk (I. Simo
sarju.mehta@addenbrookes.nhs.uk (S.G. Mehta), langping
mojgan.reza@newcastle.ac.uk (M. Reza), jorgemao@ff.up.p
robert.lightowlers@newcastle.ac.uk (R.N. Lightowlers), rob
(R. McFarland), robert.taylor@newcastle.ac.uk, robert.tayl
zofia.chrzanowska-lightowlers@ncl.ac.uk (Z.M.A. Chrzano
1 Permanent address: College of Medicine, Taif Univ
Arabia.
2 Permanent address: REQUIMTE, Department of Drug
University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-3
0925-4439/$ – see front matter © 2013 The Authors. Pub
http://dx.doi.org/10.1016/j.bbadis.2013.10.008a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 July 2013
Received in revised form 30 September 2013
Accepted 17 October 2013
Available online 24 October 2013
Keywords:
Mitochondria
Mitochondrial disease
Aminoacyl-tRNA synthetase
Aminoacylation
Mitochondrial translation
Protein synthesisMitochondrial aminoacyl-tRNA synthetases (aaRSs) are essential enzymes in protein synthesis since they charge
tRNAs with their cognate amino acids. Mutations in the genes encoding mitochondrial aaRSs have been associ-
ated with a wide spectrum of human mitochondrial diseases. Here we report the identification of pathogenic
mutations (a partial genomic deletion and a highly conserved p. Asp325Tyr missense variant) in FARS2, the
gene encoding mitochondrial phenylalanyl-tRNA synthetase, in a patient with early-onset epilepsy and isolated
complex IV deficiency in muscle. The biochemical defect was expressed in myoblasts but not in fibroblasts and
associated with decreased steady state levels of COXI and COXII protein and reduced steady state levels of the
mt-tRNAPhe transcript. Functional analysis of the recombinantmutant p. Asp325Tyr FARS2 protein showed an in-
ability to bind ATP and consequently undetectable aminoacylation activity using either bacterial tRNA or human
mt-tRNAPhe as substrates. Lentiviral transduction of cells with wildtype FARS2 restored complex IV protein
levels, confirming that the p.Asp325Tyr mutation is pathogenic, causing respiratory chain deficiency and neuro-
logical deficits on account of defective aminoacylation of mt-tRNAPhe.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.aaRS, aminoacyl-tRNA synthe-
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Human mitochondria possess their own translation machinery in
order to produce 13 mitochondrially-encoded polypeptides that are sub-
units of the oxidative phosphorylation (OXPHOS) complexes. The transla-
tion machinery has a dual origin and comprises mitochondrially (mt-)
encoded transfer RNAs (mt-tRNAs) and ribosomal RNAs (mt-rRNAs)
as well as numerous, nuclear-encoded proteins including mitochondrial
ribosomal proteins, initiation, elongation and termination factors, a
methionyl-tRNA transformylase andmitochondrial aminoacyl-tRNA syn-
thetases. Hence, mutations in either themitochondrial genome (mtDNA)
[1,2] or the nuclear DNA [3] can cause defects in mitochondrial protein
synthesis resulting in a variety of mitochondrial disease phenotypes af-
fecting both children and adults.
Aminoacyl-tRNA synthetases (aaRSs) play a key role in the faithful
translation of the genetic code since they catalyse the attachment of
each amino acid to its cognate tRNA. The human proteome includes
two sets of aaRSs that are encoded by nuclear genes and are involved
in either cytosolic or mitochondrial protein synthesis [4], with the ex-
ception of GARS and KARS that function in both domains. Based on theved.
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into two classes: Class I aaRSs (mainly active as monomers) and Class II
enzymes (mainly active as dimers or tetramers) [5]. In recent years,
recessively-inherited mutations in a growing number of mitochondrial
aminoacyl-tRNA synthetases of both classes have been associated with
a diverse spectrum of early-onset mitochondrial clinical presentations
[6]. These include mutations in the genes for DARS2 causing leukoen-
cephalopathy with brain stem and spinal cord involvement and lactate
elevation (LBSL) [7,8], RARS2 causing pontocerebellar hypoplasia type
6 (PCH6) [9], YARS2 causing myopathy, lactic acidosis and sideroblastic
anaemia (MLASA) syndrome [10,11], SARS2 causing hyperuricemia, pul-
monary hypertension, renal failure in infancy and alkalosis (HUPRA)
syndrome [12], HARS2 associated with ovarian dysgenesis and sensori-
neural hearing loss [13], AARS2 causing infantile cardiomyopathy [14],
EARS2 associatedwith leukoencephalopathy [15],MARS2 causingneuro-
degenerative phenotype in flies and autosomal recessive spastic ataxia
frequently associated with leucoencephalopathy (ARSAL) in humans
[16], LARS2 associated with premature ovarian failure and hearing loss
in Perrault syndrome [17] and KARS, which encodes both the cytosolic
and mitochondrial lysl-tRNA synthetases, and is associated with non-
syndromic hearing impairment [18]. Recently, mutations have been re-
ported in the FARS2 (mitochondrial phenylalanyl-tRNA synthetase)
gene in two families with infantile mitochondrial encephalopathy rem-
iniscent of Alpers' syndrome [19,20]. In the present study, we report
novel FARS2 mutations including a large scale genomic deletion, in a
child with muscle-restricted OXPHOS deficiency associated with intrac-
table infantile epilepsy and abnormal brain MRI findings.
2. Material and methods
2.1. Patient case report
This young boy is the first child of healthy non-consanguineous,
white British parents. He was born at term following an uneventful
pregnancy weighing 3132 g (9th–25th centile). Early development
was thought to be normal. At approximately 6months of age he devel-
oped tonic upward eye deviation associatedwith flexion of his arms and
neck consistent with infantile spasms. An electroencephalograph (EEG)
at this time was grossly abnormal (hypsarrhythmia) and strongly sup-
ported a diagnosis of West Syndrome. Cranial MRI was reported as nor-
mal. Prednisolone was prescribed and treated the seizures effectively.
Steroids were weaned over 6weeks and he remained seizure free for a
further 6 months. By the age of 1 year, it was apparent that his earlyA B
Fig. 1. Cranial MRI performed at age 2.5 years. A. Transverse T1 FLAIR image illustrating symm
demonstrating thinning of the anterior and mid portions of the corpus callosum.developmental progress was not being maintained and that he was
functioning at the 6–8 month developmental stage. Seizures returned
shortly after his first birthday and were prolonged, frequent and on oc-
casion focal, involving his right arm, leg and right side of face. Clonaze-
pam briefly improved seizure frequency, but subsequently his epilepsy
has proved refractory to various combinations of anticonvulsant thera-
py. Prolonged seizures of more than 60min have been associatedwith a
stepwise regression in his neurodevelopment. Seizure semiology is now
predominantly one of epilepsia partialis continua involving the right
side of his face, right arm and right leg. The development of focal sei-
zures and the progressive nature of the condition prompted a second
cranialMRI at the age of 2years 6months. By contrast with the previous
scan, this MRI revealed symmetrical subcortical white matter lesions
(Fig. 1A) with thinning of the anterior and genu of the corpus callosum
(Fig. 1B).
On examination, thepatient had small, round, anteriorly rotated ears
and a broad nasal root. He demonstrated no visual awareness but star-
tled to loud noise. Tone was increased in all 4 limbs with internal rota-
tion of both legs at the hips. Reflexes were pathologically brisk. Brief
myoclonic jerks were evident throughout the examination.
2.2. Structural investigation of the nuclear genome using genome-wide array
Early genetic screening included an Affymetrix Genome-wide
Human SNP 6.0 array, which was used to detect DNA copy number
changes in our patient. Samples were prepared and processed accord-
ing to the manufacturer's specifications and analysed using locally-
established methods [21]. Array CEL intensity files were loaded into
Genotyping Console (Affymetrix UK Ltd.) for analysis. An approximate-
ly 88kb deletion was identified within the short arm of chromosome 6,
band p25.1 but no similar deletions were identified in the controls. This
reported deletion was interrogated against ~5000 control samples
using Nexus Copy Number v6.1TM (BioDiscovery Inc.). Quantitative po-
lymerase chain reaction (qPCR) using the SYBR-Green method was
used to confirm the reported deletion and determine the inheritance
pattern [21]. Identification of the genes within the reported deletion
locus was achieved using the UCSC genome browser build GRCh36/
hg18 at the time.
2.3. LYRM4 and FARS2 gene sequencing
Total genomic DNA was obtained using standard methods and the
coding region plus intron–exon boundaries of the LYRM4 and FARS2etrical, anterior predominant, white matter signal changes. B. Sagittal T1 weighted image
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in Supplemental Table S1). Ampliconswere sequenced using the BigDye
v3.1 kit and capillary electrophoresed on the ABI3130xl fluorescent se-
quencing platform (Life Technologies,Warrington,UK). Chromatograms
were compared to corresponding GenBank reference sequences, LYRM4
NM_020408.4; FARS2 NM_006567.3. All sequence variants were cross-
referenced against dbSNP (build 135) then investigated using in silico
methodologies.
2.4. In silico prediction tools
Amino acid residue conservation and predicted impact of the novel
FARS2 variant was analysed using Ensembl release 66 [22], Polyphen2
[23], SIFT [24] and AlignGVGD [25].
2.5. Mitochondrial genome sequencing
Whole mtDNA genome sequencing was performed on DNA derived
from muscle as described previously [26].
2.6. Tissue culture manipulations
Primary fibroblast andmyoblast cultureswere established from skin
and muscle biopsies and propagated in a humidified incubator with 5%
CO2 at 37°C. Fibroblasts were cultured in Eagle's Minimal Essential Me-
dium supplemented with 2 mM L-glutamine, 1× non-essential amino
acids and 10% foetal calf serum (FCS). Myoblasts were grown in Skeletal
Muscle Cell Growth Medium (PromoCell GmbH, Heidelberg Germany)
with Supplement Mix (Epidermal Growth Factor, basic Fibroblast
Growth Factor, and Insulin), 10% foetal calf serum, 50μg/ml streptomy-
cin and 50 U/ml penicillin and 2 mM L-glutamine. Lentiviral particles
containing wild-type FARS2 were purchased from Genecopoeia (LP-
10240-Lv105-0200-S). Cells were infected overnight, following viral in-
fection, transduced cells were selected with 2 μg/ml puromycin.
2.7. Respiratory chain enzyme activity
Activities of the individual respiratory chain complexes (complexes
I–IV) and citrate synthase were determined spectrophotometrically as
previously described [27].
2.8. SDS-PAGE and Western blotting
Cells were harvested then lysed in lysate buffer (50mM Tris 7.5 pH,
130mM NaCl, 2mM MgCl2, 1mM PMSF and 1% NP-40 (v/v)). Proteins
(20–50 μg) were separated by 10% SDS-PAGE and electroblotted onto
PVDF membrane (Immobilon-P, Millipore Corporation). Membranes
were sequentially probed using the following commercially available an-
tibodies: FARS2 (PTG Labs, 16436-1-AP), Complex II SDHA 70 kDa
(MitoSciences,MS204),β-actin (Sigma, A1978), COX I (Molecular probes
A6403), COX II (Molecular probes, A6404), NDUFB8 (MitoSciences,
MS105), NDUFS3 (MitoSciences, MS110) and NDUFA9 (MitoSciences,
MS111). Secondary antibodies were HRP conjugated and detection was
by chemiluminescence (ECL + Kit, Amersham) according to the
manufacturer's instructions and visualised with PhosphorImager/
ImageQuant software (Molecular Dynamics, GE Healthcare).
2.9. RNA isolation and high-resolution northern blotting
Total RNA was extracted from cultured cells using TRIzoLTM
(Invitrogen). Samples (2 μg) were electrophoresed through 15% dena-
turing polyacrylamide gels. Separated RNA was electroblotted onto a
GeneScreen Plus membrane (PerkinElmer, Beaconsfield, UK) and fixed
by UV crosslinking prior to hybridization with radiolabelled probes.
Probes for mt-tRNAPhe, mt-tRNAVal and mt-tRNALeu were produced by
PCR amplification using the following primers (GenBank accessionnumber for human mtDNA: NC_019290.1): human mt-tRNALeu(UUR)
forward (position 3200–3219) 5′-TATACCCACACCCACCCAAG-3′ and re-
verse (position 3353–3334) 5′-GCGATTAGAATGGGTACAAT-3′; human
mt-tRNAPhe forward (position 552–570) 5′-CCAAACCCCAAAGACACCC-
3′ and reverse (position 712–694) 5′-GAACGGGGATGCTTGCATG-3′;
human mt-tRNAVal forward (position 1579–1598) 5′-CTGGAAAGTG
CACTTGGACG-3′ and reverse (position 1734–1714) 5′-GGGTAAATGG
TTTGGCTAAGG-3′. Purified PCR products were labelled with [α-32P]
dCTP (250 μCi, 3000 Ci/mmol; Perkin Elmer) using random hexamers
and free nucleotides were removed by gel filtration. Hybridization was
carried out overnight at 42°C in 5× SSPE, 1% SDS, 10% (w:v) dextran sul-
phate, 50% (v:v) formamide and 5× Denhardt's solution. Membranes
were stringently washed before detection of signal by Phosphor-
Imager/ImageQuant software.
2.10. Metabolic labelling of mitochondrial protein synthesis
Essentially as previously described [28], growing cells in culture
were incubated with
35
S methionine/cysteine (2 mCi, 1175 Ci/mmol;
Perkin Elmer) for 2 h in methionine- and cysteine-free DMEM (Sigma)
to radiolabel the newly synthesised mitochondrial proteins. Radio-
labelling was restricted to mtDNA encoded proteins by including
100μg/ml emetine hydrochloride (Sigma) in the medium to inhibit cy-
tosolic protein synthesis. A cell lysate (30 μg) was then prepared and
separated through 15% SDS-PAGE followed by overnight fixation in 3%
(v:v) glycerol, 10% (v:v) glacial acetic acid, 30% (v:v) methanol. The
gel was then vacuum dried at 60°C, placed into a PhosphorImager cas-
sette for 24–120 h and analysed by PhosphorImager/ImageQuant soft-
ware. It was subsequently rehydrated and Coomassie blue stained to
confirm equal loading.
2.11. Relative quantification of mtDNA
Total DNA was extracted from cultured myoblasts by standard
methods.MT-ND4was selected as the mtDNA marker and 18S as a nu-
clear DNAmarker against which to normaliseND4 value. The primer se-
quences were: ND4 forward 5′-CCATTCTCCTCCTATCCCTCAAC-3′ and
reverse 5′-CACAATCTGATGTTTTGGTTAAACTATATTT-3′; and 18S for-
ward 5′-GTAACCCGTTGAACCCCATT-3′ and reverse 5′-CCATCCAATCGG
TAGTAGCG-3′. qPCR was performed (LightCycler® Nano, Roche Diag-
nostics) using the FastStart Essential DNA Green Master (Roche Diag-
nostics). CT values were calculated automatically by the software and
the relative quantification was determined using the ΔΔCT method.
2.12. Analysis of mitochondrial morphology and nucleoids
Myoblasts were grown on 35 mm plates as described earlier. Cells
were incubated with 3 μl/ml PicoGreen (Quant-ITTM) for 1 h in culture
media. Tetramethylrhodaminemethyl ester (5nMTMRM+, Invitrogen)
was added for the final 15min of incubation and kept in the assay buffer
(135mMNaCl, 5mM KCl, 0.4mM KH2PO4, 1.3mM CaCl2, 1mMMgSO4,
5.5 mM glucose and 20 mM HEPES; pH 7.4 with NaOH) throughout
washing and imaging. Imaging was performed at 63× magnification
with an inverted fluorescence microscope (Axiovert 200M, Carl Zeiss)
equipped with FITC and Texas Red filters.
2.13. Expression and purification of human FARS2
FARS2 amplicons were generated from IMAGE clone 5088776/MGC
31883 (BC021112.1) by standard 35cycle PCR using a proofreading po-
lymerase (KOD Hot Start Novagen) and the following primers, forward
5′-CACACAGGATCCGCAGAGTGTGCCACCCAAAG-3′ and reverse 5′-CAC
ACAGGATCCAGCCTGAGTGAAGTGGTGAC 3′, incorporating BamHI re-
striction sites (underlined). PCRproductswere digested prior to ligation
into BamHI linearized pGEX-6P-1, using a Rapid DNA Ligation Kit (Ther-
mo Scientific) according to manufacturer's instructions. The construct
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transform competent Escherichia coli Tuner cells (Novagen) and subse-
quently as a template to generate a mutant copy of FARS2 by site-
directed mutagenesis using the Quikchange procedure (Stratagene).
Both fusion proteins were expressed following induction with 1 mM
IPTG at 37 °C for 4 h and affinity purified using Glutathione Sepharose
™ 4B.Wild-type andmutant FARS2were released by PreScission prote-
ase (GE Healthcare) in elution buffer (0.75 ml PBS, 1 mM DTT, 1 mM
EDTA and 48U PreScission protease).
2.14. Template production, in vitro transcription and purification of human
mitochondrial tRNAPhe
A construct was generated containing the T7 RNA polymerase pro-
moter sequence, followed by the hammerhead ribozyme sequence, up-
stream of the mt-tRNAPhe sequence after which was positioned a BstNI
site. This was achieved using the following overlapping primers: for-
ward 5′-GTAATACGACTCACTATGGGAGATCTGCTGATGAGTCCGTGAG
GACGA AACGGTACCCGGTACCGTCGTTTATGTAGCTTACCTC-3′ and re-
verse 5′-GTCCTGGTGTTTATGGGGTGATGTGAGCCCGTCTAAACATTTTCA
GTGTATTGCTTTGAGGAGGTAAGCTACATAAAC-3′. Following annealing
and extension, this double stranded product was cloned into SmaI line-
arized pUC18 and used to transform E. coli α-select chemically compe-
tent cells (Bioline). Plasmid DNA was then purified and sequenced to
validate the construct. This was then linearised with BstNI and in vitro
transcribed using AmpliScribe™ T7-Flash™ Transcription Kit according
to the manufacturer's instructions (Epicentre, Madison, WI). RNA was
incubated (1h at 55 °C) in buffer containing 30mM MgCl2 and 40mM
Tris–HCl (pH 8.0) to facilitate self-cleavage by the hammerhead ribo-
zyme. This ensured the exact mt-sequence at the 5′ terminus rather
than the T7 consensus motif. Purified RNA was separated by 15% dena-
turing PAGE. Fully cleaved mt-tRNAPhe was recovered from the gel in
elution buffer (1M NH4OAc, 2mM EDTA and 0.2% (w/v) SDS).
2.15. Functional analysis of recombinant mutant FARS2
In vitro aminoacylation assays were performed essentially as de-
scribed [29], in a 25μl volume at 30°C for 20min using 50μM
3
H phenyl-
alanine (1 mCi, 126.2 Ci/mmol; Perkin Elmer), 4 μg tRNA and 2–4 μg
enzyme in buffer containing 50 mM Tris–HCl pH 7.75, 12 mM MgCl2,
10mM KCl, 0.2 μg/ml BSA and 2.5mM ATP as described. Prior to addi-
tion, tRNAs were heated for 2min at 60 °C and cooled down slowly to
room temperature. At different time points, 5 μl aliquots were spotted
onto Whatman 0.45 μM nitrocellulose membrane and precipitated in
ice cold 5% trichloroacetic acid. Incorporation of radioactive phenylala-
nine was measured by liquid scintillation counting. Furthermore, to as-
sess ATP binding only, reactions under similar conditions were
performed using 2 mM γATP (250 μCi, 3000 Ci/mmol; Perkin Elmer)
and 4 μg enzyme. Incorporation of radioactive ATP was measured by
Cerenkov counter.
3. Results
3.1. Cytogenetic and molecular genetic analysis
Karyotyping revealed no abnormalities, whilst high resolution array
CGH of the index case revealed an interstitial subtelomeric 6p25.1 dele-
tion, sized at 88kb,with analysis of familial samples confirmingpaternal
(and grandpaternal) inheritance. Analysis of the breakpoints,
chr6:5193613–5281294 (hg19), revealed two RefSeq genes within the
locus, LYRM4 and FARS2, both of which are partially deleted — the 3′
exons of LYRM4 and the regulatory region of the FARS2 gene, including
the promoter and untranslated exon 1 (Fig. 2A). Subsequent molecular
genetic analysis of the LYRM4 gene revealed no known or potentially
pathogenic mutations, whilst a novel heterozygous c.973GNT
transversionwas identified in exon 5 of FARS2, predicting a p.Asp325Tyramino acid substitution. Analysis of parental samples confirmedmater-
nal inheritance of the c.973GNT variant, supporting recessive inheri-
tance in this family (Fig. 2B). Conservation analysis revealed the
p.Asp325 residue shows a moderate degree of evolutionary conserva-
tion (Fig. 2C), whilst in silico predictions using PolyPhen, AlignGVGD
and SIFT support a deleterious effect on protein function. Analysis of
themitochondrial genome revealed no known or potentially pathogen-
ic mtDNAmutations, thereby excluding the possibility of a novel or ma-
ternally transmitted mtDNA mutation. In particular, no mutation was
found within theMTTF gene encoding the mt-tRNAPhe molecule.
3.2. Biochemical analysis of OXPHOS activities revealed differential
expression in patient cell types
A diagnostic skeletalmuscle biopsywas obtained from the patient to
allow the assessment of respiratory chain enzyme activities. Histochem-
ical analysis revealed decreased reactivity for cytochrome c oxidase
(COX, or complex IV) (Fig. 3A), an observation confirmed by the spec-
trophotometric assay of OXPHOS components that showed complex
IV to be markedly decreased in the patient's muscle compared to con-
trols (Fig. 3B, Table 1).
Primary fibroblast andmyoblast cell lines were established from the
patient, permitting a more detailed investigation of the molecular phe-
notype and characterisation of both the biochemical defect and under-
lying molecular disease mechanism. Following the spectrophotometric
analysis of skeletal muscle, the next assays focussed on the measure-
ment of OXPHOS complex activities in patient-derived cell lines. These
appeared to indicate a tissue-specific defect. The respiratory chain en-
zyme activities were normal in patient fibroblasts, whilst patient myo-
blasts demonstrated an isolated complex IV defect, recapitulating the
observations in skeletal muscle, albeit with a lesser severity (Fig. 3B,
Table 1).We next examined the expression of FARS2 protein and sever-
al respiratory chain components. Western blot analysis demonstrated
that the steady state levels of FARS2 was reduced in the patient. Most
mt-aaRSs appear to be present at low levels and so isolated mitochon-
dria rather than cell lysates were analysed for steady state levels of
FARS2 protein. The patient exhibited levels that were approximately
50% of control, consistent with expression from only the maternally
inherited allele (Fig. 3C). Interestingly the p.Asp325Tyr mutation did
not appear to affect stability. The mitochondrially-encoded COXI and
COXII subunits of complex IVwere normal in patient fibroblasts but de-
creased in patient myoblasts when compared to age-matched controls
(Fig. 3C). In contrast, normal levels of the complex I protein NDUFB8,
which is sensitive to CI assembly defects, was observed in both fibro-
blasts and myoblasts. These findings were consistent with the pattern
of respiratory chain enzyme deficiency— an isolated complex IV defect
associated with the FARS2mutations, only seen in the patient's mature
muscle or myoblasts (Fig. 3B, Table 1).
3.3. FARS2 mutations affected mt-tRNAPhe steady state levels in myoblasts.
To study the effect of the FARS2mutations on the steady state levels
of mt-tRNAPhe, high resolution northern blotting was performed using
total RNA extracted from patient myoblasts. The levels of mt-tRNAVal
and mt-tRNALeu(UUR) were used as loading controls and the level of
mt-tRNAPhe was assessed as a percentage relative to controls. We ob-
served an approximately 54% reduction in the level of mt-tRNAPhe
when compared with normal controls (Fig. 3D).
3.4. De novo mitochondrial protein synthesis was not affected by the FARS2
mutations
To determine whether the FARS2 mutations led to impaired mito-
chondrial protein synthesis, we next evaluated the incorporation of
35
S-methionine/cysteine into de novo synthesised mitochondrial pro-
teins in patient myoblasts, compared to age-matched control cells.
AB
Proband
Father
Mother
Control
C
Fig. 2.Molecular characterisation of novel FARS2mutations. A. Heterozygous 88kb deletion identified on Array CGH; B. Sequencing chromatograms, arrow indicates thematernally trans-
mitted novel c.973GNT, p.Asp325Tyr FARS2 variant. C. Alignment of the FARS2 protein sequence flanking the position of the amino acid change from eukaryotic organisms (yeast, worms,
flies, fish and mammals) indicating the conservation of the p.Asp325 amino acid.
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levels of both complex IV subunits and mt-tRNAPhe, no significant
decrease was observed in the de novo synthesis of mitochondrial pro-
teins (Fig. 3E).
3.5. Altered distribution of mitochondrial nucleoids
The dynamic mitochondrial network and the distribution of nucle-
oids within were examined in patientmyoblasts using fluorescencemi-
croscopy following TMRM and PicoGreen staining. No observable
differences were found in either mitochondrial morphology or number
(Fig. 4A). The distribution of themitochondrial reticulum appeared nor-
mal in patient cells compared to controls.Wedid observe, however, that
nucleoidswere consistently found to be both larger and fewer in patient
myoblasts (Fig. 4A). After assessing the mtDNA copy number it was
clear that this change in nucleoid presentation was not associated
with an observable decrease in mtDNA, as the levels in patient cells
fell within normal limits (Fig. 4B).
3.6. Functional analysis of p.Asp325Tyr recombinant FARS2 indicated a
significant decrease in both aminoacylation capacity and ATP binding
To investigate if the FARS2mutation in the patient cells was respon-
sible for compromised mt-tRNA aminoacylation efficiency, we assessed
in vitro aminoacylation activity of a recombinant FARS2 protein
engineered to carry the identical p.Asp325Tyrmissensemutation as ob-
served in our patient. Both themutant and wild-type recombinant pro-
teins were assessed for monodispersion prior to activity assays. Wildtype FARS2 showed good activity on both the bacterial tRNA and
human mt-tRNAPhe. As expected this activity was ATP dependent
(Fig. 5A). In contrast,mutant FARS2 protein showednodetectable activ-
ity on either bacterial or humanmt-tRNAPhe substrate even in the pres-
ence of ATP (Fig. 5A). In addition, we examined the previously reported
crystal structure of FARS2 [30], upon which we superimposed the pre-
dicted structure of the p.Asp325Tyr mutant. Themodest distortion sug-
gested that the FARS2 mutation would widen the ATP binding pocket
and thus decrease affinity for ATP (Fig. S1). Therefore, we further
assessed the ability of both mutant and wild-type FARS2 to bind ATP
in vitro. As predicted, wild type FARS2 protein showed high levels of
ATP binding in contrast to the mutant p.Asp325Tyr FARS2 protein,
which showed no detectable ATP binding (Fig. 5B).3.7. Transduction of patientmyoblasts restored the steady state level of both
OXPHOS polypeptides and mt-tRNAPhe
Immortalised patient and control myoblasts were transducedwith a
lentiviral construct that would express wild type FARS2. Following anti-
biotic selection to propagate transduced cells, RNA and cell lysates were
prepared. Similar analyses to those already described were performed
on cell lines following transduction to examine steady state levels of
both OXPHOS polypeptides andmt-tRNAs. AlthoughWestern blot anal-
ysis is at best semi-quantitative, steady state levels of mitochondrial
aminoacyl tRNA synthetases does generally appear to be very low re-
quiring high amounts of mitochondrial protein to allow detection [31].
The transduction procedure was performed simultaneously for both
control and patient myoblasts, and although the level of FARS2
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Fig. 3. Effect of FARS2mutation onmitochondrial homeostasis. A. Cytochrome c oxidase (COX)histochemistry of thepatientmuscle showed a generalised loss of enzyme activity compared
to age-matched control tissue. B. Respiratory chain enzyme activity inmuscle biopsy, fibroblast andmyoblast: activities of complex I, complex II, and complex IVwere determined in con-
trol (blue) and patient (red) and normalised to citrate synthase. Results are based on three independent measurements and are shown as percent of the mean control value± standard
deviation C. Steady state levels of RC proteins in fibroblasts (left panel) andmyoblasts (right panel) were determined byWestern blotting. 10% SDS-PAGEwas performedwith cell lysates
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sitometric analyses were performed on all blots. A representative example is presented with the values relative to controls for the signals derived for each tRNA below the sample. E. De
novomitochondrial protein synthesis in control myoblast (lane C) and the patientmyoblast cells (lane P). Designation of proteins is as described by [28]. A section of Coomassie blue (CBB)
stained gel is shown indicate equal loading.
61A. Almalki et al. / Biochimica et Biophysica Acta 1842 (2014) 56–64expression became significantly increased in both lines, the expression
levels appeared to be even higher in the patient (Fig. 6A, cf C1 vs P).
Analysis of steady state levels of mitochondrially encoded COXI and
COXII, which were lower than control in untransduced cells, were
now restored, even exceeding control levels. Similarly following trans-
duction, analysis of mt-tRNAPhe levels indicated an increase from ~46%
to N90% relative to control (Fig. 6B cf lanes 2 and 4). Transduction ap-
peared to leave levels of mt-tRNAVal and mt-tRNALeu(UUR) unchanged
(Fig. 6B). Together these data indicate that replacement of wild type
FARS2 was sufficient to restore levels of mt-tRNAPhe and complex IV
polypeptides.4. Discussion
We have identified a patient with early-onset epilepsy and isolated
complex IV deficiency due to mutations in the FARS2 gene, prompted
by diagnostic array CGH studies that identified a heterozygous intersti-
tial 6p25.1 deletion. Scrutiny of the genes within the 88 kb deleted re-
gion revealed two genes, LYRM4 and FARS2, 1both predicted to have a
mitochondrial function. LYRM4 encodes a protein required for nuclear
and mitochondrial iron–sulphur protein biosynthesis, whilst FARS2 en-
codes the mitochondrial phenylalanyl-tRNA synthetase. At the time of
referral, neither the LYRM4 or FARS2 genes had been reported in
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Table 1
Spectrophotometric activity measurements of OXPHOS complexes.
Skeletal muscle biopsy Fibroblast Myoblast
Patient Controls Patient Controls Patient Controls
(Mean± SD, n= 25) (Mean± SD, n= 8) (Mean± SD, n=4)
Complex I 0.093 0.104 0.195 0.197 0.139 0.151
nmol NADH oxidised·min−1·unit citrate synthase−1 ±0.036 ±0.043 ±0.042
Complex II 0.110 0.145 0.187 0.219 0.165 0.126
nmol DCPIP reduced·min−1·unit citrate synthase−1 ±0.047 ±0.067 ±0.013
Complex IV 0.318 1.124 1.081 1.083 0.601 1.084
×10−3 K s−1·unit citrate synthase−1 ±0.511 ±0.186 ±0.105
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directionally sequenced. Since then a mutation in LYRM4 has been iden-
tified in patients with combined OXPHOS disease [32]. The affected indi-
viduals were homozygous for the mutation and manifested withdeficiencies in respiratory chain complexes I, II and III, as well as
aconitase and ferrochelatase, all of which contain iron sulphur clusters
[32]. This presentation differed to our patient and no potentially patho-
genic mutations were identified within the LYRM4 gene. Analysis of the
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Fig. 6. Lentiviral transduction ofmyoblastswithwildtype FARS2. Both control (C1) and pa-
tient (P) myoblasts were transduced with lentivirus designed to express wildtype FARS2.
Images are representative of a minimum of n = 3. A. Following selection cell lysates
(40 μg) were subjected to Western blot analysis to determine the levels of FARS2 and
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and 4) lentiviral transduction with wild type FARS2.
63A. Almalki et al. / Biochimica et Biophysica Acta 1842 (2014) 56–64FARS2 gene, however, revealed a novel heterozygous c.973GNT
transversion, predicting a p.Asp325Tyr amino acid substitution. Whole
mtDNAgenome sequencingwas undertaken and excluded the possibility
of a co-existing mtDNA point mutation, particularly within the mt-
tRNAPhe (MTTF) gene. Investigations into the consequences of a FARS2
mutation were therefore pursued.
The FARS2 protein has fourmajor domains: anN-terminal region (res-
idues 1–83), a catalytic domain (residues 84–325), a linker region (resi-
dues 326–358) and a C-terminal domain (residues 359–451). The
maternally-transmitted p.Asp325Tyr FARS2mutation is located in the cat-
alytic domainwhere the aminoacylation reaction occurs. Based on the re-
ported crystal structure of FARS2 [30], we predict that this mutation will
disrupt ATP binding, affecting aminoacylation efficiency. Consistent with
an inability to bind ATP, we found a significant reduction in the amino-
acylation capacity of the recombinant mutant protein in vitro, where ac-
tivity was essentially undetectable. This was also consistent with the
complex IV deficiency observed in the patient's muscle biopsy, the de-
creased steady state levels of COXI and COXII protein expression in myo-
blasts and in the reduced steady-state levels of themt-tRNAPhe transcript.
These low levels of protein and mt-tRNA were relieved by transduction
with awild type copy of FARS2 confirming that themutationwas respon-
sible for the biochemical phenotype and clinical presentation.
Unlikemanymitochondrial disorders, where there is often vast clin-
ical heterogeneity with a given genotype, a rapidly increasing numberof mitochondrial tRNA synthetase genes are being reported in associa-
tion with very discrete clinical phenotypes and syndromes. For exam-
ple, DARS2 mutations are associated with LBSL [7], YARS2 mutations
with MLASA [10] and RARS2 mutations with PCH6 [9]. Interestingly, a
recent report describes novel FARS2 mutations in two families with
fatal intractable myoclonic epilepsy [20]; whilst the initial presenting
symptom clearly correlates with our index case, there was no evidence
of marked cerebral atrophy in our patient's brain MRI, which was a
striking feature in the cases presented by these authors, although our
patient did have structural brain abnormalities involving the corpus
callosum and white matter abnormalities.
Clinical phenotypes caused by mutations in the specific mt-
aminoacyl-tRNA synthetases are associated with diversity in both
tissue-specificity and clinical presentation [6]. Variability in clinical pre-
sentationmay suggest the involvement of these enzymes in a secondary
function besides their primary role in mitochondrial protein synthesis,
however, these have not yet been identified. Tissue-specificity may
arise due to variation in the level of gene expression between tissues,
which will designate that the enzyme activity will be either above or
below the critical threshold in a particular tissue. In addition, differences
in requirements for respiratory chain complexes activity and ATP pro-
duced by oxidative phosphorylation may also lead to the presence or
absence of the phenotype in a particular tissue. In our patient, the respi-
ratory chain complex IV deficiencywas observed in bothmaturemuscle
and myoblasts but not in patient fibroblasts; this is not unprecedented
and has been observed in other mt-aminoacyl-tRNA synthetase defects
including YARS2 [11]. Moreover, we might have expected to observe
multiple respiratory chain defects in these tissues, rather than an isolat-
ed complex IV defect, given the role of mt-aminoacyl-tRNA synthetases
in mitochondrial translation; again, variability in the biochemical de-
fects observed in human mt-aminoacyl-tRNA synthetase disorders has
been reported, withMARS2mutations leading to isolated complex I de-
ficiency [16]. There is no clear explanation for this and it does not appear
to be related to the phenylalanine content of mtDNA-encoded COX sub-
units (Supplemental Table S2). Despite the biochemical defects ob-
served in myoblasts, we were not able to demonstrate a marked
deficiency in de novomitochondrial protein synthesis. Thismay, howev-
er, reflect a low level of residual aminoacylation activity that is sufficient
to promote elongation under experimental conditions, where cells are
essentially glycolytic.
To the best of our knowledge, the identification of a microdeletion
represents a novel diseasemechanism in associationwith a primarymi-
tochondrial presentation; 6p25 deletions represent a rare but clinically
characterised cytogenetic microdeletion syndrome, with less than 15
interstitial deletion cases reported in the literature to date [33,34]. The
smallest deletion reported in association with the 6p25 deletion
64 A. Almalki et al. / Biochimica et Biophysica Acta 1842 (2014) 56–64syndrome is 900 kb and involves the CDYL, RPP40, PP1R3G, LYRM4 and
FARS2 genes [33]. Bozza et al. have hypothesised that these genes are re-
sponsible for the characteristic 6p25 deletion syndrome features, given
that the phenotype correlates to that of other deletion syndrome cases,
whose deletions span up to 500Mb of the 6p25 region. Our patient pre-
sentedwith intractable infantile epilepsy (a feature never before report-
ed in association with the 6p25 microdeletion syndrome) and a much
smaller deletion than previously reported thereby prompting further
investigation of the affected genes for a possible recessive aetiology.
Our patient is reported to have minor dysmorphic features involving
the nasal root and the ears, whilst these dysmorphic features have not
previously been reported in association with recessively-inherited
FARS2 defects, they have been reported in patients with a classic 6p25
microdeletion syndrome. Thesefindings suggest that haploinsufficiency
of the LYRM4 and FARS2 genes may be, at least in part, responsible for
some of the dysmorphic features of the 6p25 deletion syndrome.
In conclusion, we demonstrate that compound heterozygous FARS2
mutations lead to an early-onsetmitochondrial disease phenotype asso-
ciated with respiratory chain dysfunction and characterised by infantile
spasms that evolved into refractory focal epilepsy, neurodevelopmental
regression and the development of subcortical white matter abnormal-
ities on cranial MRI. Given the increasing influence of targeted exome
capture and next generation sequencing to identify novel genes associ-
ated with early-onset mitochondrial disease, including several mt-
aminoacyl-tRNA synthetases such as AARS2 [14] and EARS2 [15], our
study nicely demonstrates that routine diagnostic genetic testingmeth-
odologies including array CGH can be crucial in the identification of un-
derlying genetic defects. This may be of particular relevance to patients
who have an as yet undetermined genetic defect following exome se-
quencing and principally those in whom single heterozygous nuclear
gene defects have been identified.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.10.008.
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